Condition: Prostate Cancer · Stereotactic Body Radiation Therapy · Sponsor: Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients and second generation hormonal treatments (Apalutamide/Abiraterone+Prednisone/Enzalutamide) vs androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients plus second generation hormonal treatments, for the treatment of oligometastatic prostate cancer.
This description comes directly from the study's public registry record.
Antonio J Conde Moreno, MD PhD · +34 649039866 · antoniojconde@gmail.com
Fernando López Campos, MD PhD · +34 663158959 · fernando_lopez_campos@hotmail.com
Always discuss trial participation with your own doctor first.
| Hospital Universitario Ramón y Cajal | Madrid, Spain | Recruiting |
| Hospital Universitari i Politècnic La Fe | Valencia, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05209243